Vitamin D, Calcium Did Not Reduce Risk for Colorectal Adenoma Recurrence

Article

Patients with a prior history of colorectal adenomas saw no reduction in the risk for recurrence with the use of a daily supplement of vitamin D, calcium, or both.

Patients with a prior history of colorectal adenomas saw no reduction in the risk for recurrence with the use of a daily supplement of vitamin D, calcium, or both, according to the results of a study published in the New England Journal of Medicine.

“Contrary to our hypotheses, neither 1000 IU of vitamin D3 nor 1200 mg of calcium, taken daily alone or in combination, reduced the risk of colorectal adenomas,” wrote researcher John A. Baron, MD, of the University of North Carolina at Chapel Hill, and colleagues.

Based on epidemiologic data suggesting that higher levels of vitamin D and calcium reduced risk for colorectal neoplasia, Baron and colleagues designed this study to explore the use of daily supplementation of vitamin D, calcium, or both for the prevention of colorectal adenomas.

The study included 2,259 patients who had recently been diagnosed with adenomas and had no known polyps remaining after complete colonoscopy. The patients were randomly assigned to daily 1,000 IU vitamin D3, 1,200 mg calcium as carbonate, both, or neither. All patients underwent a follow-up colonoscopy 3 or 5 years from baseline.

About 88% of patients who underwent randomization reported taking 80% of their tablets during the first year of the trial with this number decreasing to about 74% by the final year of treatment. The mean increase in serum 25-hydroxyvitamin D levels was 7.93 ng/mL among those patients assigned to vitamin D.

During the follow-up period, 3,131 lesions that were “potentially neoplastic” were diagnosed in 1,301 of the study participants; 880 participants were ultimately diagnosed with adenomas (43%).

The use of daily supplementation had no significant effect on the risk for recurrence, even among those participants with lower baseline levels of serum 25-hydroxyvitamin D.

The risk ratio for participants assigned vitamin D compared with those who were not was 0.99 (95% confidence interval [CI], 0.89–1.09); the risk among those taking calcium compared with those who were not was 0.95 (95% CI, 0.85–1.06). The risk ratio among participants taking both supplements compared with those taking calcium alone was 1.01 (95% CI, 0.88–1.15) and compared with those taking neither was 0.93 (95% CI, 0.80–1.08).

“We have no ready explanation for the finding with regard to calcium supplementation, but the lack of an observational association between the risk of adenomas and baseline dietary calcium intake in our population supports it,” the researchers wrote. “Our findings with regard to vitamin D are not inconsistent with a modest chemopreventive potential, but they do not support the more marked chemopreventive effect that has sometimes been posited.”

A subgroup analysis did reveal a decreased risk for adenomas among participants assigned to calcium supplementation with lower body mass index; however, the researchers wrote that “because of the number of subgroups examined, this finding may be due to chance.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Related Content